Antibe Therapeutics Inc(Pre-Merger) ATBPF

RE:Study finds lower risk of heart attack with Naproxen

[PoorOpinion]

SergeantSanderz wrote: There's been some chatter on the board recently about CV issues and different NSAIDs.  However, a study by the Evidence-based Practice Center of the Agency for Healthcare Research and Quality (an agency of the US Department of Health and Human Services, which is similar to Health Canada) found through a review of 360 published studies that naproxen poses the lowest risk of heart attack.  The study is from 2006 and remains an often-cited reference today.

Here's the link:
 
https://archive.ahrq.gov/news/press/pr2006/nsaidpr.htm

Of course, the implications for ATB-346 are obvious as relative CV safety is one of the key points.  And think of the implications when using the much smaller dose of ATB-346 compared to naproxen, which will probably result in even greater relative CV safety (less drug, less side effect).

JMO, SergeantSanderz

Sections of industry and the science literature have support the idea of a lower risk for naproxen, I posted links to two reviews saying so. Other sections have shown that the risk is similar, Merck published the PRECISION study in 2016 that showed their COX-2 has the same risk as Naproxen and Ibuprophen, the picture is mixed. The FDA position is that no distinction can be made between different Nsaids, their view is really what matters to us. BTW the EMA distinguish between Nsaids. The FDA may change that position with the lastest review. What probably really matter is that they clarify the position on how to measure these things and from Antibe's perpective what data will be required to provide meaning. If you read the discussion over the 24,000 patient PRECISION study there is even talk about whether it is sufficient.